Aprepitant

Therapeutic indications

Aprepitant is indicated for:

Prevention of nausea and vomiting associated with chemotherapy

Population group: both men and women, only adults (18 years old or older)

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 80-125 mg once daily

Prevention of nausea and vomiting associated with chemotherapy

Population group: both men and women, only adolescents (12 years - 18 years old)

Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adolescents from the age of 12.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 80-125 mg once daily

Contraindications

Aprepitant is contraindicated in the following cases:

Pimozide, terfenadine, astemizole, cisapride

at least one of
Pimozide

Terfenadine

Astemizole

Cisapride

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines